CAJ | 학술논문

　　慢性淋巴细胞白血病（CLL）存在很大的临床异质性。尽管免疫化疗方案的进步带来了显著的疗效，部分患者仍可在短期内发生疾病进展，或处于疾病难治耐药的状态。由于移植物抗CLL效应的存在，异基因造血干细胞移植的根治性意义获得肯定。年轻CLL患者如具有高危因素，包括：嘌呤类似物耐药或治疗后早期复发，以及具有17p（TP53位点）缺失和TP53突变，异基因造血干细胞移植是合理的治疗选择。减低强度的预处理方案有效降低了患者的治疗相关死亡率。
　　만성림파세포백혈병（CLL）존재흔대적림상이질성。진관면역화료방안적진보대래료현저적료효，부분환자잉가재단기내발생질병진전，혹처우질병난치내약적상태。유우이식물항CLL효응적존재，이기인조혈간세포이식적근치성의의획득긍정。년경CLL환자여구유고위인소，포괄：표령유사물내약혹치료후조기복발，이급구유17p（TP53위점）결실화TP53돌변，이기인조혈간세포이식시합리적치료선택。감저강도적예처리방안유효강저료환자적치료상관사망솔。
Chronic lymphocytic leukemia(CLL) is an indolent lymphoproliferative disorder with great clinical heterogeneity. The immunochemotherapeutic regimens have improved the outcome of majority of the patients. Nonetheless, in some patients, the disease progresses shortly after the immunochemotherapy, while in others, it becomes refractory and drug resistant. Allogeneic hematopoietic stem cell transplantation(allo-SCT) potentially cures CLL due to the graft versus CLL effect. It has been wildly accepted that allo-SCT is a good option for young CLL patients with high risk factors, including purine analogue resistance, early relapse after purine analogue-based treatment, and 17p deletion and TP53 mutation. Reduced-intensity conditioning regimens effectively decrease the treatment-related mortality.